BEDFORD, Mass., Nov. 20, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced the groundbreaking imaging products it will highlight at the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place, Chicago from December 1st through 5th.
"The RSNA annual meeting is the largest medical show in the United States and the largest radiology show in the world," said Jack Cumming, Hologic's President and Chief Executive Officer. "It's the time of the year when we get the chance to meet with clinical professionals and demonstrate what we have been working on and what the healthcare community can expect from us in the year ahead. With a footprint of 12,800 square feet, the entire Hologic exhibit is focused on showing innovative technologies that identify diseases earlier, improve patient outcomes and optimize workflow efficiencies."
Hologic is dedicating a significant share of its RSNA exhibit to the clinical benefits of 3D mammography in breast cancer screening and diagnosis, and Hologic's recently introduced lower dose 3D mammography and 3D guided breast biopsy capabilities.
Hologic's 3D Selenia Dimensions mammography system is currently the only FDA approved 3D system in the United States, and Hologic is the only company worldwide that can provide a 3D breast biopsy solution. The Company has 3D systems placed in 49 states and 59 countries worldwide.
Hologic's 3D mobile coach is making a special stop at RSNA on its year-long, cross-country "3D Technology: A More Accurate Mammogram" tour which is dedicated to spreading the word about the important clinical benefits of 3D mammography.
2013 was a pivotal year for 3D mammography with the publication of multiple large-scale, clinical studies validating the benefits of this groundbreaking technology. The studies published to date show that Hologic's screening technology results in an approximate 40% increase in invasive cancer detection rates ii-iv and up to a 40% reduction in recalls iv-v. Continuing the trend, over 60 new scientific papers, poster sessions and sponsored courses will be presented at RSNA on 3D mammography, many of which used Hologic's 3D technology.
The Hologic exhibit also dedicates space to conventional digital mammography, breast ultrasound and magnetic resonance imaging (MRI), breast biopsy, image analytics, accelerated partial breast irradiation and bone densitometry products – all part of the total solution Hologic can offer its customers.
Three new Hologic products of particular note include:
The 99th Scientific Assembly and Annual Meeting of the RSNA is expected to attract over 60,000 attendees. The RSNA is an international society of radiologists, medical physicists and other medical professionals with 55,000 members from more than 140 countries.
Follow Hologic on Twitter (@hologic) for the latest news and updates from RSNA.
About Hologic, Inc.:Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. To learn more visit www.hologic.com.Hologic, Affirm, ATEC, C-View, Dimensions, Eviva, Horizon, ImageChecker, MultiView, Selenia and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statement Disclaimer:This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's systems and applications. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems and applications can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.Contacts: Marianne McMorrowJim CulleyGlobal PR and Advertising PublicistSr. Director of MarketingHologic, Inc.Hologic, Inc.Marianne.McMorrow@Hologic.comJim.Culley@Hologic.comTel: +1 781 999 7723Tel: +1 781 999 7583 i – v For references please visit: http://www.hologic.com/media/2013-RSNA-Press-Release-References.pdf
|SOURCE Hologic, Inc.|
Copyright©2012 PR Newswire.
All rights reserved